Evidence map›Paper›PMID 24999598›Full record

ArticleThe Journal of investigative dermatology2014

Primary melanoma tumors from CDKN2A mutation carriers do not belong to a distinct molecular subclass.

Johan Staaf, Katja Harbst, Martin Lauss, Markus Ringnér, Anna Måsbäck, Jillian Howlin, Karin Jirström, Mark Harland, Abdlsattar Zebary, Jane M Palmer and 7 more

Abstract readLetterMulticenter Study
PubMed Publisher
In one paragraph

Article in The Journal of investigative dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Johan StaafDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Katja HarbstDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Martin LaussDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Markus RingnérDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Anna MåsbäckDepartment of Clinical Pathology, Skåne University Hospital, Lund, Sweden.
Jillian HowlinDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Karin JirströmDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; Department of Clinical Pathology, Skåne University Hospital, Lund, Sweden.
Mark HarlandSection of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
Abdlsattar ZebaryDepartment of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Jane M PalmerQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Christian IngvarDepartment of Dermatology, LUMC, Leiden, The Netherlands.
Håkan OlssonDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Julia Newton-BishopSection of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
Johan HanssonDepartment of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Nicholas HaywardQIMR Berghofer Medical Research Institute, Brisbane, Australia.
Nelleke GruisDepartment of Dermatology, LUMC, Leiden, The Netherlands.
Göran JönssonDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. Electronic address: goran_b.jonsson@med.lu.se.

Funding

Cancer Research UK 10589
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

HeterozygoteAdolescentAdultAgedAged, 80 and overAustraliaCase-Control StudiesCyclin-Dependent Kinase Inhibitor p16EuropeFemaleGene Expression ProfilingGTP PhosphohydrolasesHumansMaleMelanomaMembrane ProteinsBRAF protein, humanCyclin-Dependent Kinase Inhibitor p16GTP PhosphohydrolasesMembrane ProteinsNRAS protein, humanProto-Oncogene Proteins B-raf

Identifiers

PMID24999598

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.